PSMA-RADS to improve evaluation and management of prostate cancer.

IF 2.3 3区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Abdominal Radiology Pub Date : 2024-12-20 DOI:10.1007/s00261-024-04738-2

Niloufar Rafiei Alavi, Maryam Rahmani, Arti Gupta, Vahid Yaghmai

{"title":"PSMA-RADS to improve evaluation and management of prostate cancer.","authors":"Niloufar Rafiei Alavi, Maryam Rahmani, Arti Gupta, Vahid Yaghmai","doi":"10.1007/s00261-024-04738-2","DOIUrl":null,"url":null,"abstract":"Prostate-Specific Membrane Antigen (PSMA) positron emission tomography (PET) / computed tomography (CT) has become essential in managing prostate cancer, offering superior diagnostic accuracy. The introduction of the U.S. Food and Drug Administration (FDA)-approved theranostic agent (177Lutetium-PSMA-617) has further enhanced the significance of PSMA PET/CT imaging. Despite its benefits, PSMA-PET/CT is not without challenges, as PSMA expression is not exclusive to prostate cancer cells. Therefore, standardized interpretation criteria are necessary for consistent and reliable communication among physicians. The PSMA- reporting and data system (RADS) provides a structured approach for assessing PSMA-PET/CT scans. Updated in 2023, PSMA-RADS 2.0 addresses previous limitations and introduces a new category, PSMA-RADS 5T, for treated metastases. This system categorizes lesions based on their likelihood of prostate cancer involvement, improving longitudinal monitoring and guiding management strategies. By familiarizing radiologists with PSMA-RADS through case-based reviews, this primer aims to enhance diagnostic accuracy and treatment planning for patients with prostate cancer.","PeriodicalId":7126,"journal":{"name":"Abdominal Radiology","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Abdominal Radiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00261-024-04738-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Prostate-Specific Membrane Antigen (PSMA) positron emission tomography (PET) / computed tomography (CT) has become essential in managing prostate cancer, offering superior diagnostic accuracy. The introduction of the U.S. Food and Drug Administration (FDA)-approved theranostic agent (¹⁷⁷Lutetium-PSMA-617) has further enhanced the significance of PSMA PET/CT imaging. Despite its benefits, PSMA-PET/CT is not without challenges, as PSMA expression is not exclusive to prostate cancer cells. Therefore, standardized interpretation criteria are necessary for consistent and reliable communication among physicians. The PSMA- reporting and data system (RADS) provides a structured approach for assessing PSMA-PET/CT scans. Updated in 2023, PSMA-RADS 2.0 addresses previous limitations and introduces a new category, PSMA-RADS 5T, for treated metastases. This system categorizes lesions based on their likelihood of prostate cancer involvement, improving longitudinal monitoring and guiding management strategies. By familiarizing radiologists with PSMA-RADS through case-based reviews, this primer aims to enhance diagnostic accuracy and treatment planning for patients with prostate cancer.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

PSMA-RADS 改善前列腺癌的评估和管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Abdominal Radiology Medicine-Radiology, Nuclear Medicine and Imaging

CiteScore

5.20

自引率

8.30%

发文量

334

期刊介绍： Abdominal Radiology seeks to meet the professional needs of the abdominal radiologist by publishing clinically pertinent original, review and practice related articles on the gastrointestinal and genitourinary tracts and abdominal interventional and radiologic procedures. Case reports are generally not accepted unless they are the first report of a new disease or condition, or part of a special solicited section. Reasons to Publish Your Article in Abdominal Radiology: · Official journal of the Society of Abdominal Radiology (SAR) · Published in Cooperation with: European Society of Gastrointestinal and Abdominal Radiology (ESGAR) European Society of Urogenital Radiology (ESUR) Asian Society of Abdominal Radiology (ASAR) · Efficient handling and Expeditious review · Author feedback is provided in a mentoring style · Global readership · Readers can earn CME credits